Xeris Pharmaceuticals Inc share price logo

Xeris Pharmaceuticals Inc

NASDAQ: XERS

Small Cap

$6.26

+0.14

(+2.29%)

as on

Xeris Pharmaceuticals Inc Stock Performance

as on May 2, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $6.10
    $6.33
    downward going graph

    2.56%

    Downside

    1.12%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $4.26
    $10.08
    downward going graph

    32.03%

    Downside

    61.02%

    Upside

    downward going graph

Xeris Pharmaceuticals Inc share price movements today

Previous Close
$6.12
Open
$6.17
Volume
1.4M
Day's Low - High
$6.10 - $6.33
52 Week Low - High
$4.26 - $10.08

Xeris Pharmaceuticals Inc Historical Returns

1 Month Return
+ 1.41 %
3 Month Return
-16.78 %
1 Year Return
+ 36.72 %
3 Year Return
+ 151.02 %
5 Year Return
0 %

Xeris Pharmaceuticals Inc Stock Fundamentals & Key Indicators

Check Xeris Pharmaceuticals Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$1.1B

EPS (TTM)

0.1597

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

37.1M

Revenue (TTM)

291.8M

Profit Margin

0.19%

Return On Equity TTM

-617.16%

Xeris Pharmaceuticals Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Xeris Pharmaceuticals Inc with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Xeris Pharmaceuticals Inc image
Xeris Pharmaceuticals Inc
BUY$1.1BNANA0.19%
Alnylam Pharmaceuticals Inc image
Alnylam Pharmaceuticals Inc
BUY$40.2B120.06%129.828.45%
Vertex Pharmaceuticals Inc image
Vertex Pharmaceuticals Inc
BUY$107.7B95.87%27.6332.94%
BeiGene, Ltd. image
BeiGene, Ltd.
NA$32.3BNA117.735.37%
Regeneron Pharmaceuticals Inc image
Regeneron Pharmaceuticals Inc
BUY$72.0B46.91%16.5431.41%

Stock Returns calculator for Xeris Pharmaceuticals Inc Stock including INR - Dollar returns

The Xeris Pharmaceuticals Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

Xeris Pharmaceuticals Inc investment value today

Current value as on today

₹1,56,730

Returns

₹56,730

(+56.73%)

Returns from Xeris Pharmaceuticals Inc Stock

₹39,732 (+39.73%)

Dollar Impact

₹16,998 (+17%)

Analyst Recommendation on Xeris Pharmaceuticals Inc Stock

Based on 12 analysts

BUY

91.67%

Buy

8.33%

Hold

0.00%

Sell

Based on 12 analysts, 91.67% of analysts recommend a 'BUY' rating for Xeris Pharmaceuticals Inc. Average target price of $11.14

Xeris Pharmaceuticals Inc Share Price Target

Get share price movements and forecasts by analysts on Xeris Pharmaceuticals Inc.

What analysts predicted

43.81%UPSIDE

Target Price

$11.14

Current Price

$6.26

Analyzed by

12 Analysts

Target

$11.14

Xeris Pharmaceuticals Inc target price $11.14, a slight upside of 43.81% compared to current price of $6.26. According to 12 analysts rating.

Xeris Pharmaceuticals Inc Stock’s Investor Sentiment and Interest

Search interest for Xeris Pharmaceuticals Inc Stock has decreased by -38% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-38% versus previous 30 day period

Xeris Pharmaceuticals Inc Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Total Revenue
48
44
40
48
54
60
60
71
74
85
Gross Profit
40
34
34
37
40
50
51
56
63
66
Operating Income
-4
-9
-14
-8
-12
1
-3
4
6
16
EBITDA
-2
-3
-8
-3
-8
5
1
8
11
14
Interest Expense
6
7
7
7
7
7
7
7
7
7
Depreciation
2
3
3
3
3
3
3
3
3
3
Income Before Tax
-12
-13
-18
-14
-19
-5
-9
-1
0
11
Income Tax Expense
0
0
0
0
-3
-
-
-
-
-
Net Income
-12
-13
-18
-15
-15
-5
-9
-1
0
11
Net Profit Margin
-25.23%
-30.16%
-46.71%
-31.22%
-29.00%
-8.51%
-15.34%
-2.70%
0.83%
12.91%

Xeris Pharmaceuticals Inc Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
1
1
2
2
2
49
110
163
203
291
Gross Profit
1
1
2
1
1
36
87
135
166
238
Operating Income
-13
-26
-59
-122
-122
-115
-81
-44
-33
24
EBITDA
-13
-26
-57
-119
-117
-113
-69
-23
-13
12
Interest Expense
0
0
2
7
7
7
14
26
33
29
Depreciation
-
0
0
1
1
1
12
13
12
12
Income Before Tax
-13
-26
-60
-126
-126
-122
-96
-63
-57
0
Income Tax Expense
0
0
1
0
0
0
-1
-1
-2
-
Net Income
-13
-26
-60
-125
-125
-122
-94
-62
-54
0
Net Profit Margin
-1228.74%
-1706.56%
-2437.32%
-4613.52%
-4613.52%
-247.48%
-85.86%
-37.98%
-27.00%
0.19%

Xeris Pharmaceuticals Inc Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
-13
-18
-15
-15
-5
-9
-1
0
11
Operating Cash Flow
6
-20
-10
-8
1
-10
0
18
20
Investing Cash Flow
14
-19
4
9
10
0
0
0
0
Financing Cash Flow
0
35
0
0
0
-3
0
13
0
Change in Cash
21
-4
-5
1
12
-13
0
32
19

Xeris Pharmaceuticals Inc Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-26
-60
-125
-91
-122
-94
-62
-54
0
Operating Cash Flow
-24
-56
-104
-80
-95
-102
-47
-36
28
Investing Cash Flow
0
-68
-2
-27
97
34
-6
4
0
Financing Cash Flow
35
128
80
126
27
127
-1
36
11
Change in Cash
9
3
-26
18
29
59
-54
4
39

Global Institutional Holdings in Xeris Pharmaceuticals Inc

Funds
Holdings
Qube Research & Technologies
2.1%
State Street Corp
2.17%
JPMorgan Chase & Co
1.09%
UBS Group AG
1.07%
BlackRock Inc
7.18%
See all

Xeris Pharmaceuticals Inc News & Key Events

    Insights on Xeris Pharmaceuticals Inc

    Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

    • imgPOSITIVE IMPACT

      Best in 3 Years

      img

      In the last 3 years, XERS has outperformed top 5 stocks with highest market-cap in its industry

    • imgPOSITIVE IMPACT

      Best in 1 Year

      img

      In the last 1 year, XERS has outperformed top 5 stocks with highest market-cap in its industry

    • imgPOSITIVE IMPACT

      Revenue Rich

      img

      Revenue is up for the last 8 quarters, 40.63M → 85.80M (in $), with an average increase of 10.0% per quarter

    • imgPOSITIVE IMPACT

      Profit Spike

      img

      Netprofit is up for the last 4 quarters, -9.22M → 11.08M (in $), with an average increase of 294.4% per quarter

    • imgNEGATIVE IMPACT

      Price Dip

      img

      In the last 6 months, XERS stock has moved down by -36.9%

    About Xeris Pharmaceuticals Inc

    Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
    OrganisationXeris Pharmaceuticals Inc
    Headquarters1375 West Fulton Street, Chicago, IL, United States, 60607
    IndustryBiotechnology
    CEOMr. John P. Shannon
    E-voting on sharesClick here to vote

    Key Management of Xeris Pharmaceuticals Inc

    Name

    Title

    Mr. John P. Shannon

    CEO & Director

    Mr. Kevin McCulloch

    President & COO

    Mr. Steven M. Pieper

    Chief Financial Officer

    Ms. Beth P. Hecht J.D.

    Chief Legal Officer & Corporate Secretary

    FAQs

    What is Xeris Pharmaceuticals Inc share price today?

    Xeris Pharmaceuticals Inc share price today is $6.26 as on at the close of the market. Xeris Pharmaceuticals Inc share today touched a day high of $6.33 and a low of $6.1.

    What is the 52 week high and 52 week low for Xeris Pharmaceuticals Inc share?

    Xeris Pharmaceuticals Inc share touched a 52 week high of $10.08 on and a 52 week low of $4.26 on . Xeris Pharmaceuticals Inc stock price today i.e. is closed at $6.26,which is 37.90% down from its 52 week high and 47.12% up from its 52 week low.

    What is Xeris Pharmaceuticals Inc's market capitalisation today?

    Xeris Pharmaceuticals Inc market capitalisation is $0.00T as on .

    How to invest in Xeris Pharmaceuticals Inc Stock (XERS) from India?

    1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
    2. Step 2: Search for Xeris Pharmaceuticals Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Xeris Pharmaceuticals Inc Shares that will get you 0.2396 shares as per Xeris Pharmaceuticals Inc share price of $6.26 per share as on May 2, 2026 at 1:29 am IST.

    What is the minimum amount required to buy Xeris Pharmaceuticals Inc Stock (XERS) from India?

    Indian investors can start investing in Xeris Pharmaceuticals Inc (XERS) shares with as little as ₹94.88 or $1 (as of ) using the INDmoney app.
    For example: If you want to invest $10 or ₹948.80 in Xeris Pharmaceuticals Inc stock (as per the Rupee-Dollar exchange rate as on ). Based on Xeris Pharmaceuticals Inc share’s latest price of $6.26 as on May 2, 2026 at 1:29 am IST, you will get 1.5974 shares of Xeris Pharmaceuticals Inc. Learn more about fractional shares .